title: Letter: lessons from the 'real-world' entecavir therapy in chronic hepatitis B patients--authors' reply.
authors.affiliation: Division of Gastroenterology & Hepatology, Oregon Health & Science University, Portland, OR, USA. ahnj@ohsu.edu.
authors.forename: J
authors.initials: J
authors.lastname: Ahn
authors.affiliation: Division of Gastroenterology & Hepatology, Stanford University, Stanford, CA, USA.
authors.forename: M H
authors.initials: MH
authors.lastname: Nguyen
authors.affiliation: Digestive Diseases, Yale University, New Haven, CT, USA.
authors.forename: J K
authors.initials: JK
authors.lastname: Lim
authors.affiliation: Gastroenterology/Hepatology Division, Tufts Medical Center, Boston, MA, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Lee
authors.affiliation: Department of Medicine, NYU Langone, New York, NY, USA.
authors.forename: C Q
authors.initials: CQ
authors.lastname: Pan
authors.affiliation: Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Lok
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008297:Male
chemical_list: D000998:Antiviral Agents; D006147:Guanine